Xenpozyme

Xenpozyme (olipudase alfa) is an enzyme replacement therapy for acid sphingomyelinase deficiency. This overview covers its therapeutic role and practical considerations for use. Xenpozyme is indicated for long-term enzyme replacement in ASMD types A/B.

Olipudase alfa is used as an enzyme replacement therapy to address acid sphingomyelinase deficiency (ASMD), a rare genetic disorder. It helps manage symptoms by replacing the missing enzyme needed for lipid metabolism. This medication is prescribed for patients with confirmed ASMD to support overall health and reduce disease-related complications. It is not a cure but helps control symptoms over time.

As an enzyme replacement therapy, olipudase alfa works by supplementing the deficient enzyme in ASMD patients. This supports the breakdown of lipids in cells, which may help reduce organ enlargement and improve metabolic function. Patients may experience improved energy levels and reduced disease-related discomfort over time.

Olipudase alfa is administered under medical supervision due to the risk of infusion-related reactions. Patients should be monitored for hypersensitivity during and after administration. It is important to discuss any pre-existing conditions or allergies with a healthcare provider before starting treatment.

Limited data exists on drug interactions with olipudase alfa. However, caution is advised when combining with other medications that may affect immune response or metabolism. Patients should inform their healthcare provider about all medications, including over-the-counter and herbal products, to assess potential risks.